Abstract
Type 2 Diabetes Mellitus (T2DM) is the most challenging health issue of the
21st century; it results from a complex interaction between multiple gene and
environmental factors. TCF7L2 encodes a transcription factor that is involved in the
Wnt signaling pathway that regulates gene expression of pro-glucagon. Effective
treatment is needed to properly manage T2DM patients. Currently, 5 major classes of
oral pharmacological agents are available for the treatment of T2DM, like metformin,
sulfonylureas, meglitinides, thiazolidinedione, and alpha-glucosidase inhibitors
Keywords: TCF7L2, Wnt signaling, Pharmacological agent, Type 2 diabetes mellitus
Related Journals
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents
Endocrine, Metabolic & Immune Disorders - Drug Targets
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)
Current Diabetes Reviews
Related Books
Epidemiology of Type 2 Diabetes
Frontiers in Clinical Drug Research-Diabetes and Obesity
Frontiers in Clinical Drug Research-Diabetes and Obesity
Frontiers in Clinical Drug Research-Diabetes and Obesity
Frontiers in Clinical Drug Research-Diabetes and Obesity
Frontiers in Clinical Drug Research-Diabetes and Obesity
Frontiers in Clinical Drug Research-Diabetes and Obesity
Frontiers in Clinical Drug Research-Diabetes and Obesity
Hypercalcemia Pathophysiology & Treatment
Microcirculation and Insulin Resistance